


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition ~~Composition~~ containing an androgenic 11 β -halogen steroid, ~~selected from the group of compounds of general of~~ formula I



in which

X-Y-Z represents a ~~group with one of the two structures~~ CH=C-C or CH₂-C=C,

R¹ can be in α -position and β -position and stands for hydrogen, R or P-Q-R that is bonded via P to the basic ring structure, provided that no substituent R¹ is present on Z if X-Y-Z represents the group CH₂-C=C, whereby

P and Q each independently represents a represent straight-chain or branched-chain C₁- to C₈-alkylene, -alkenylene, or -alkynylene group groups or a fluorinated straight-chain or branched-chain C₁- to C₈-alkylene, -alkenylene, or -alkynylene group their fluorinated derivatives and can be the same or different, and whereby

R represents a CH₃ or CF₃ radical, provided that no substituent R¹ is present on Z if X-Y-Z represents the group CH₂-C=C,

R^6 is a hydrogen atom or stands for R or P-Q-R that is bonded via P to the ring structure ~~can have the meanings that are indicated under R^7 ,~~

R^7 stands for R or P-Q-R that is bonded via P to the basic ring structure, ~~whereby these groups have the previously mentioned meanings,~~

R^{11} represents a halogen,

R^{13} is methyl or ethyl, and

R^{17} is hydrogen or stands for $C(O)-R^{18}$, ~~whereby~~

R^{18} is a straight-chain or branched-chain C_1 - to C_{18} -alkyl, -alkenyl, or -alkinyl radical or an aryl radical, or stands for T-U-V that is bonded via T ~~P~~ to the $C(O)$ group, which R^{18} group is optionally substituted with one or more $NR^{19}R^{20}$ or SO_xR^{21} ,

x ~~is 0, 1 or 2,~~

R^{19}, R^{20}

and R^{21} ~~in each case are hydrogen or T-U-V that is bonded via T to N or S, whereby~~


T and U each independently represents a ~~represent~~ straight-chain or branched-chain C_1 - to C_{18} -alkylene, -alkenylene, -alkinylene group groups, alicyclic C_3 - to C_{12} group groups or aryl group groups and are the same or different, and

V is a straight-chain or branched-chain C_1 - to C_{18} -alkyl-, -alkenyl- or -alkinyl radical or an aryl radical, ~~or~~

R^{18} ~~has one of the previously mentioned meanings and in addition is substituted with one or more groups $NR^{19}R^{20}$ or one or more groups SO_xR^{21} , whereby x = 0, 1 or 2, and R^{19}, R^{20} and R^{21} in each case are hydrogen or T-U-V that is bonded via T to N, S with the previously mentioned meaning,~~

or a pharmaceutically acceptable salt thereof ~~provided that in addition, the physiologically compatible addition salts with inorganic and organic acids are included,~~

and the gestagen of the formula below:




2. (Currently Amended) The composition ~~Composition~~ according to claim 1, wherein the compound of ~~characterized in that the~~ 11β-halogen steroid of general formula I is ~~the compound~~ 11β-fluoro-17β-hydroxy-7α-methyl-estr-4-en-3-one.

3. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ composition containing a composition according to claim 1 and ~~as well as~~ a pharmaceutically compatible vehicle and/or adjuvant ~~adjuvants~~.

4. (Currently Amended) The pharmaceutical ~~Pharmaceutical~~ composition according to claim 3, wherein the compound of ~~11β-halogen steroid of general~~ formula I is ~~the compound~~ 11β-fluoro-17β-hydroxy-7α-methyl-estr-4-en-3-one.

5. (Currently Amended) A male ~~Male~~ contraceptive agent, which is a combination of an androgenic 11β-halogen steroid of formula I



in which

X-Y-Z represents $\text{CH}=\text{C}-\text{C}$ or $\text{CH}_2-\text{C}=\text{C}$,

R^1 can be in α -position and β -position and stands for hydrogen, R or P-Q-R that is bonded via P to the ring structure, provided that no substituent R^1 is present on Z if X-Y-Z represents $\text{CH}_2-\text{C}=\text{C}$,

P and Q each independently represents a straight-chain or branched-chain C_1 - to C_8 -alkylene, -alkenylene, or -alkynylene group or a fluorinated straight-chain or branched-chain C_1 - to C_8 -alkylene, -alkenylene, or -alkynylene group

R represents a CH_3 or CF_3 radical,

R^6 is a hydrogen atom or stands for R or P-Q-R that is bonded via P to the ring structure,

R^7 stands for R or P-Q-R that is bonded via P to the ring structure,

R^{11} represents a halogen,

R^{13} is methyl or ethyl,

$\text{R}^{17'}$ is hydrogen or stands for $\text{C}(\text{O})-\text{R}^{18}$,

R^{18} is a straight-chain or branched-chain C_1 - to C_{18} -alkyl, -alkenyl, or -alkynyl radical or an aryl radical, or stands for T-U-V that is bonded via T to the $\text{C}(\text{O})$ group, which R^{18} group is optionally substituted with one or more $\text{NR}^{19}\text{R}^{20}$ or SO_xR^{21} ,

x is 0, 1 or 2,

R¹⁹, R²⁰


and R²¹ in each case are hydrogen or T-U-V that is bonded via T to N or S,

T and U each independently represents a straight-chain or branched-chain C₁- to C₁₈-alkylene, -alkenylene, -alkynylene group, alicyclic C₃- to C₁₂ group or aryl group,

V is a straight-chain or branched-chain C₁- to C₁₈-alkyl-, -alkenyl- or -alkynyl radical or an aryl radical,

or a pharmaceutically acceptable salt thereof,

and the gestagen of the formula below



containing a pharmaceutical composition according to claim 3.

6. (Currently Amended) The male Male contraceptive agent according to claim 5, wherein the compound of formula I is 11 β -fluoro-17 β -hydroxy-7 α -methyl-estr-4-en-3-one containing a pharmaceutical composition according to claim 4.

7. (Currently Amended) The male Male contraceptive agent according to claim 5, wherein the androgenic compound of general formula I is formulated

pharmaceutically such that it is suitable to the latter can be implanted in the body of ~~the a~~ male user ~~over an extended period~~ such that the androgenic compound is released continuously as an extended release formulation to ~~over this extended period to the organism~~ of the user.

8. (Currently Amended) The male ~~Male~~ contraceptive agent according to claim 5, wherein the androgenic compound of ~~general~~ formula I is provided therein for oral administration.

9. (Currently Amended) The male ~~Male~~ contraceptive agent according to claim 5, wherein the gestagen therein is formulated pharmaceutically such that it is released to the body of the male user as an extended release formulation ~~over an extended period~~.

10. (Currently Amended) The male ~~Male~~ contraceptive agent according to claim 9, wherein the gestagen is formulated such that it is suitable to the latter can be implanted in the body of ~~a the~~ male user over an extended period, such that the gestagen is released continuously as an extended release formulation to ~~over this extended period to the organism of the user~~.


11. (Currently Amended) The male ~~Male~~ contraceptive agent according to claim 10, wherein the gestagen is formulated such that it is suitable for administration transdermally in a transdermal system.

12. (Currently Amended) The male ~~Male~~ contraceptive agent according to claim 5, wherein the gestagen is formulated for oral administration.

13. (New) A method of male contraception, comprising administering to a male a composition according to claim 1.

14. (New) A method of male contraception, comprising administering to a male a composition according to claim 2.

15. (New) A method of male contraception, comprising administering to a male an androgenic 11 β -halogen steroid of formula I



in which

X-Y-Z represents CH=C-C or CH₂-C=C,

R¹ can be in α -position and β -position and stands for hydrogen, R or P-Q-R that is bonded via P to the ring structure, provided that no substituent R¹ is present on Z if X-Y-Z represents CH₂-C=C,

P and Q each independently represents a straight-chain or branched-chain C₁- to C₈-alkylene, -alkenylene, or -alkynylene group or a fluorinated straight-chain or branched-chain C₁- to C₈-alkylene, -alkenylene, or -alkynylene group

R represents a CH₃ or CF₃ radical,

R⁶ is a hydrogen atom or stands for R or P-Q-R that is bonded via P to the ring

structure,

R^7 stands for R or P-Q-R that is bonded via P to the ring structure,

R^{11} represents a halogen,

R^{13} is methyl or ethyl,

R^{17} is hydrogen or stands for $C(O)-R^{18}$,

R^{18} is a straight-chain or branched-chain C_1 - to C_{18} -alkyl, -alkenyl, or -alkinyl radical or an aryl radical, or stands for T-U-V that is bonded via T to the C(O) group, which R^{18} group is optionally substituted with one or more $NR^{19}R^{20}$ or SO_xR^{21} ,

x is 0, 1 or 2,

R^{19} , R^{20}


and R^{21} in each case are hydrogen or T-U-V that is bonded via T to N or S,

T and U each independently represents a straight-chain or branched-chain C_1 - to C_{18} -alkylene, -alkenylene, -alkynylene group, alicyclic C_3 - to C_{12} group or aryl group,

V is a straight-chain or branched-chain C_1 - to C_{18} -alkyl-, -alkenyl- or -alkinyl radical or an aryl radical,

or a pharmaceutically acceptable salt thereof,

and the gestagen of the formula below



16. (Currently Amended) The composition ~~Composition~~ according to claim 1, wherein the compound of ~~characterized in that the~~ 11 β -halogen steroid of general formula I is ~~the compound~~ 11 β -fluoro-17 β -hydroxy-7 α -methyl-estr-4-en-3-one.